Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.76 |
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.63 |
| ▸ | CA9 | Q16790 | 6/20 | 0.63 |
| ▸ | CA1 | P00915 | 5/20 | 0.63 |
| ▸ | CA2 | P00918 | 5/20 | 0.63 |
| ▸ | CA7 | P43166 | 5/20 | 0.63 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.57 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548243 | 0.89 | KDR (0.80) | KDRTRPV1CA9CA1CA2 | |
| SCHEMBL13556584 | 0.87 | KDR (0.82) | KDRTRPV1CA9CA1CA2 | |
| SCHEMBL29364392 | 0.87 | KDR (1.00) | KDRTRPV1CA9CA1CA2 | |
| SCHEMBL118026 | 0.87 | KDR (1.00) | KDRTRPV1CA9CA1CA2 | |
| SCHEMBL20016691 | 0.86 | LMNA (0.64) | KDRTRPV1CA9CA1CA2 | |
| SCHEMBL9084296 | 0.86 | KDR (0.85) | KDRTRPV1CA9CA1CA2 | |
| SCHEMBL23235029 | 0.85 | KDR (0.74) | KDRTRPV1CA9CA1CA2 | |
| SCHEMBL14146746 | 0.85 | KDR (0.74) | KDRTRPV1CA9CA1CA2 | |
| SCHEMBL29670450 | 0.85 | KDR (0.74) | KDRTRPV1CA9CA1CA2 | |
| SCHEMBL13004799 | 0.85 | KDR (0.82) | KDRTRPV1CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932300-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932300-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-11-03 | — | — | US | disclosed |
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-11-03 | — | — | US | disclosed |
| US-9421211-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-08-23 | — | — | US | disclosed |
| US-9421211-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-08-23 | — | — | US | disclosed |
| WO-2012162025-A1 | METHODS OF SELECTING CANCER PATIENTS FOR TREATMENT WITH N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2010138820-A2 | N,N-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | NSUN2, EIF2AK2, RNGTT | KDR 4697/4885TRPV1 4318/4885CA9 4852/4885 |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | NSUN2, EIF2AK2, RNGTT | KDR 4697/4885TRPV1 4318/4885CA9 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.